Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daplusiran/Tomligisiran Followed by Bepirovirsen in Chronic Hepatitis B (B-UNITED)
NCT06537414Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Nov 2024
- Primary completion
- May 2027
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Chemically Modified siRNA
- Countries
- 19
01
Overview
A Phase 2 trial of tomligisiran, bepirovirsen in Chronic Hepatitis B (CHB), sponsored by GSK. Started Nov 2024; status: active, not recruiting.
02
Drugs
tomligisiranbepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06537414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06537414.